HiFiBiO Therapeutics, a clinical-stage global biotech, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for immunotherapies
Read more about HiFiBiO Therapeutics Read More
Our Science
We apply single cell science at every stage of drug development from target discovery to predictive biomarkers, enabling rapid advancement of new therapeutics into the clinic.
Read more
Our SOAR Values
We unite under a shared mission to SOAR to new heights in science and healthcare.
Read more
CAMBRIDGE, Mass. – September 29th, 2023 – HiFiBiO Therapeutics, a clinical-stage global biotech company focusing on improving patient lives with single-cell precision, today announced the appointment of Alexandre Grassin, as the Vice President of Finance to oversee the company’s finance activities, reporting to HiFiBiO’s Founder, Chairperson, and CEO, Dr. Liang Schweizer. “I’m delighted to have … Continued
Cambridge, MA., – August 28, 2023 – HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the … Continued
CAMBRIDGE, Mass. – June 28th, 2023 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Robert Andtbacka, MD, CM, as the Chief Medical Officer to oversee the company’s clinical activities, reporting to HiFiBiO’s Founder, Chairperson, and CEO, Dr. Liang Schweizer. “I’m very excited to have such an experienced and well-recognized clinical … Continued
CAMBRIDGE, Mass. – September 29th, 2023 – HiFiBiO Therapeutics, a clinical-stage global biotech company focusing on improving patient lives with single-cell precision, today announced the appointment of Alexandre Grassin, as the Vice President of Finance to oversee the company’s finance activities, reporting to HiFiBiO’s Founder, Chairperson, and CEO, Dr. Liang Schweizer. “I’m delighted to have … Continued
HiFiBiO Therapeutics single-cell focused platform identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes
